Member Info for Chelsea11

Reasonable I think, to expect an ASCO attendance related RNS in the next few days. Fascinating to consider what impact the conference attendance bandwagon might be having on the future direction and prospects of the company.

Many other companies will be very serious about strengthening their oncology portfolio. It’s already becoming an industry scramble for dominance. Perhaps some fallout from that, is how to best determine from all options, which is the best treatment available to a patient and to be able to select that for them.

As has been said many times here, the quality of the clinical data will reveal all and we’re getting closer to the publication of that insight.

Maybe Sath also got the Tweeting Performance Manager job as well

Well we’re up 17% here this week 😁

Must be Lofas then

I’m also a tad confused and wonder if someone could help me out please.

Does any part of the RNS link in with the silencing technology from Oxford-based mAbsolve, or is that a completely different thread from the past?

Cleaner - you obviously have no idea how many companies Genmab are working with. To think that they are recruiting for senior postions in their organisation with direct relevance to Scancell is ludicrous. It is just general recruitment, the same as any other large pharma recruit all the time - should we post all their vacancies too? However I’ll give you 10 out of 10 for imagination.

With respect, I don’t understand the relevance to Scancell of these jobs at Genmab. Of course I understand they are evaluating a Scancell product but the fact they are recruiting for Director roles in their wider organisation, carries no relevance whatsoever to that in my opinion.

I’ve sent the link to Sky……………you never know.

Two of those were Loafas and Dracula, both of whom have accidentally on purpose hit the “Like” symbol.

Agreed Chester. I also think that the picture here often gets very clouded by constant reference to investments made 10+ years ago. Not suggesting at all that isn’t factually correct for some posters but it’s also a hard fact that it’s less than 4 years since Redmile liked what they saw and fully backed the company with the cash needed to accelerate progress in the clinic.

I didn’t see that cardboard wall wobble once.

Seems a few on here haven’t just looked into the abyss, they’ve fell in recently.

I guess some folk just love to whinge!

https://www.youtube.com/watch?v=ZqLT3PmOKtQ

Loafas - are you suggesting this is now toast?

There are many, globally.

In the UK, Bowers Group springs to mind.

Interesting read from the Industrial Vision Systems website:

https://www.industrialvision.co.uk/news/catalysts-of-change-how-robots-machine-vision-and-ai-are-changing-the-automotive-manufacturing-landscape

An Oxford Metrics acquisition in the AI sweetspot.

IMO, it won’t be a case of either MRNA, or DNA as an available treatment option and there will be room for both as ammo against melanoma. In the same way that there are often multiple treatment options for other diseases. Assuming of course that trial data proves they both work well.

The publicity is positive on a number of fronts. Scancell now need to get their own data published. We already know that should be this year and we’re already in April, so it’s just a handful of months away.

Nothing new at all, from “AI Powered Pharmaceutical Intelligence”

Schlum - doubt it.

From the AGM Statement made in January:

“Trading is in-line with expectations. Further information on trading will be provided when interim results for the six months ending 31 March 2024 are announced”

Interims will be in June.